DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
6	パーキンソン病	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00129181 (ClinicalTrials.gov)	January 2005	9/8/2005	Study of the Effects of Dopaminergic Medications on Dopamine Transporter Density in Subjects With Parkinson's Disease	A Single-blinded Assessment of the Short-term Effects of Cabergoline vs. Carbidopa/Levodopa on SPECT Dopamine Transporter Density in Out-patient Subjects With Parkinson's Disease	Parkinson Disease;Parkinsonian Syndrome	Drug: cabergoline;Drug: carbidopa/levodopa;Procedure: DATscan and SPECT imaging	Institute for Neurodegenerative Disorders	Pfizer;GE Healthcare	Completed	40 Years	N/A	Both	30	N/A	Austria;Germany;Italy;Spain;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00129181
(ClinicalTrials.gov)

January 2005

9/8/2005

Study of the Effects of Dopaminergic Medications on Dopamine Transporter Density in Subjects With Parkinson's Disease

A Single-blinded Assessment of the Short-term Effects of Cabergoline vs. Carbidopa/Levodopa on SPECT Dopamine Transporter Density in Out-patient Subjects With Parkinson's Disease

Parkinson Disease;Parkinsonian Syndrome

Drug: cabergoline;Drug: carbidopa/levodopa;Procedure: DATscan and SPECT imaging

Institute for Neurodegenerative Disorders

Pfizer;GE Healthcare

Completed

40 Years

N/A

Both

N/A

Austria;Germany;Italy;Spain;United Kingdom